Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Electrophilic small molecules with novel reactivity are powerful tools that enable activity-based protein profiling and covalent inhibitor discovery. Here, we report a reactive heterocyclic scaffold, 4-chloro-pyrazolopyridine (CPzP) for selective modification of proteins via a nucleophilic aromatic substitution (SAr) mechanism. Chemoproteomic profiling reveals that CPzPs engage cysteines within functionally diverse protein sites including ribosomal protein S5 (RPS5), inosine monophosphate dehydrogenase 2 (IMPDH2), and heat shock protein 60 (HSP60). Through the optimization of appended recognition elements, we demonstrate the utility of CPzP for covalent inhibition of prolyl endopeptidase (PREP) by targeting a noncatalytic active-site cysteine. This study suggests that the proteome reactivity of CPzPs can be modulated by both electronic and steric features of the ring system, providing a new tunable electrophile for applications in chemoproteomics and covalent inhibitor design.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107811PMC
http://dx.doi.org/10.1021/acschembio.4c00025DOI Listing

Publication Analysis

Top Keywords

covalent inhibitor
8
discovery tunable
4
tunable heterocyclic
4
heterocyclic electrophile
4
electrophile 4-chloro-pyrazolopyridine
4
4-chloro-pyrazolopyridine defines
4
defines unique
4
unique subset
4
subset ligandable
4
ligandable cysteines
4

Similar Publications

[Research status and future direction of irreversible EGFR-TKI in non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of nursing, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are important treatments for EGFR mutant non-small cell lung cancer (NSCLC). However, the first and second generation EGFR-TKI face clinical limitations due to acquired resistance, such as the T790M mutation. Irreversible EGFR-TKI can significantly prolong the survival of patients by enhancing the inhibition of drug-resistant mutations through the covalent binding mechanism.

View Article and Find Full Text PDF

Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.

View Article and Find Full Text PDF

Chemodynamic therapy (CDT), leveraging Fenton reactions to generate hydroxyl radicals (•OH) from intracellular hydrogen peroxide (HO), offers a promising cancer treatment strategy due to its high specificity and low systemic toxicity. However, the targeted delivery of •OH-producing prodrugs using covalent organic frameworks (COFs) remains a significant challenge. Here, we report a mitochondria-targeted COF-based nano prodrug, COF-31@P, designed for enhanced CDT efficacy.

View Article and Find Full Text PDF

CDK7 has emerged as a cancer target because of its pivotal roles in cell cycle progression and transcription. Several CDK7 inhibitors (CDK7i) are now in clinical evaluation. Identifying patients most likely to respond to treatment and early detection of tumour evolution towards resistance are necessary for optimal implementation of cancer therapies.

View Article and Find Full Text PDF

Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging.

Eur J Med Chem

September 2025

State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, PR China. Electronic address:

The Werner syndrome RecQ helicase (WRN) has recently emerged as a novel synthetic lethality target for microsatellite instability-high (MSI-H) cancers. However, available WRN inhibitors or degraders is still lacking so far. Particularly, chemically designed probes capable of degrading WRN irrespective of microsatellite status remain unexplored.

View Article and Find Full Text PDF